Serum Institute of India

The family office investment decisions are ultimately controlled by the Poonawalla family. Adar Poonawalla, as CEO of Serum Institute of India, is the most visible senior family member. The family office does not maintain a publicly disclosed CIO or investment committee structure.

The family office benefits directly from Serum Institute of India's global position in vaccine manufacturing. This generates proprietary access to healthcare and biotech companies seeking manufacturing partnerships or distribution agreements. The office does not publicly detail its sourcing methodology.

The Poonawalla family's wealth is managed through a structure that functions as a single family office, but it is not formally separated into a distinct legal entity with a separate name. Investments are made directly from the family's holding of SII equity and other personal holdings.

The family office is known to engage in direct equity investments, primarily in healthcare and biotech. It also makes real estate investments in Maharashtra. Stage preference is unclear from public records, but given the manufacturing base, late-stage and growth equity are likely.

Publicly available information does not indicate any sectors the office explicitly avoids. However, given the manufacturing-based wealth and healthcare focus, it likely does not invest in areas that conflict with SII's vaccine or pharmaceutical business.

Poonawalla Fincorp (formerly known as Magma Fincorp) is a non-banking financial company where the Poonawalla family holds a controlling stake, and Adar Poonawalla serves as chairman. It is a separate entity from Serum Institute of India but part of the family's broader investment portfolio.

The wealth originates entirely from Serum Institute of India, the vaccine manufacturing company founded by Cyrus Poonawalla in 1966. The company is the largest vaccine manufacturer by volume in the world and supplies vaccines to global immunization programs, generating billions in annual revenue.